CureTalks launches its new series featuring biotech companies at the cutting edge of innovation and breakthrough research with the purpose of bringing their contributions to the fore and informing the patient community. Hosted by Gary Petersen, this series kickstarts with Cellectar, a clinical stage biopharmaceutical company focused on the discovery, development of drugs for the treatment of cancer. Cellectar, has a targeted universal drug conjugate with a potential to be used for many cancers. This drug conjugate, CLR131 was granted Orphan Drug designation for the treatment of multiple myeloma by both the U.S. and the European Commission and is currently being evaluated in a Phase 2 and Phase 1 studies. The drug conjugate works by delivering a radioactive, toxic compound directly to tumor cells, while limiting exposure to healthy cells. Gary talked to James Caruso, CEO and Jarrod Longcor of Cellectar Biosciences about product development, clinical trials, special challenges faced by small biotech and some of the innovative products in the pipeline.